作者: Susanna Morano , Elisabetta Mandosi , Mara Fallarino , Alessandra Gatti , Claudio Tiberti
DOI: 10.1016/J.EURURO.2007.04.042
关键词: Urology 、 Diastole 、 Sildenafil 、 Placebo 、 Internal medicine 、 Endothelial dysfunction 、 Diabetes mellitus 、 Endothelium 、 Erectile dysfunction 、 Type 2 diabetes 、 Endocrinology 、 Medicine
摘要: Abstract Objective To investigate the synergic effect of propionyl L-carnitine (PLC) plus sildenafil in reducing monocyte oxidative activity and endothelial dysfunction markers diabetic patients with erectile (ED). Methods Thirty-two type 2 ED (according to International Index Erectile Function-5 [IIEF-5]) were randomized receive PLC (2g/d) alone ( n =8) or combined (50mg/d twice weekly) =8), placebo a double-blind, fixed-dose study. Monocyte (stimulation index [SI]), intercellular adhesion molecule-1 [ICAM-1], P-selectin, advanced glycation end product (AGE) levels, Doppler sonography (recording peak systolic velocity [PSV]; diastolic [EDV]; wave time [SWT]; resistive [RI]), IIEF score evaluated before after 12 wk treatment; IIEF-5 was again 4 posttreatment. Results SI reduced by treatment p =0.05). In on (with without sildenafil), correlated Conclusion more effective diabetes ED.